Can you take CJC-1295 / Ipamorelin Stack and Tesamorelin together?

There is no specific, well-documented interaction rule for combining CJC-1295 / Ipamorelin Stack and Tesamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, CJC-1295 / Ipamorelin Stack or Tesamorelin?

CJC-1295 / Ipamorelin Stack is currently fda-approved and Tesamorelin is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs Tesamorelin

Q: What is the difference between CJC-1295 / Ipamorelin Stack and Tesamorelin?

CJC-1295 / Ipamorelin Stack: The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects. Tesamorelin: Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin Stack

FDA-approved

The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.

Full profile

Tesamorelin

FDA-approved

Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.

Full profile

	CJC-1295 / Ipamorelin Stack	Tesamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination	Egrifta, Egrifta SV, TH9507, GHRH analog
Evidence	FDA-approved	FDA-approved
Dosing range	100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)	1.28mg–2mg mg, once daily (subcutaneous)
Administration	Subcutaneous injection (both compounds), Administered together in the same injection	Subcutaneous injection (abdomen, with site rotation)
Key side effects	Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)	Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia
Cited sources	2 references	5 references

Key differences

Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
Dosing units differ: CJC-1295 / Ipamorelin Stack is dosed in mcg, Tesamorelin in mg — they operate at different scales.
Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Tesamorelin is once daily (subcutaneous).
Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 5 for Tesamorelin.

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

Tesamorelin

Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.

Read the full CJC-1295 / Ipamorelin Stack profile Read the full Tesamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.